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ABSTRACT
Background Early tranexamic acid (TXA) treatment 
reduces head injury deaths after traumatic brain injury 
(TBI). We used brain scans that were acquired as part 
of the routine clinical practice during the CRASH-3 
trial (before unblinding) to examine the mechanism 
of action of TXA in TBI. Specifically, we explored the 
potential effects of TXA on intracranial haemorrhage and 
infarction.
Methods This is a prospective substudy nested within 
the CRASH-3 trial, a randomised placebo- controlled trial 
of TXA (loading dose 1 g over 10 min, then 1 g infusion 
over 8 hours) in patients with isolated head injury. 
CRASH-3 trial patients were recruited between July 2012 
and January 2019. Participants in the current substudy 
were a subset of trial patients enrolled at 10 hospitals in 
the UK and 4 in Malaysia, who had at least one CT head 
scan performed as part of the routine clinical practice 
within 28 days of randomisation. The primary outcome 
was the volume of intraparenchymal haemorrhage 
(ie, contusion) measured on a CT scan done after 
randomisation. Secondary outcomes were progressive 
intracranial haemorrhage (post- randomisation CT shows 
>25% of volume seen on pre- randomisation CT), new 
intracranial haemorrhage (any haemorrhage seen on 
post- randomisation CT but not on pre- randomisation CT), 
cerebral infarction (any infarction seen on any type of 
brain scan done post- randomisation, excluding infarction 
seen pre- randomisation) and intracranial haemorrhage 
volume (intraparenchymal + intraventricular + subdural 
+ epidural) in those who underwent neurosurgical 
haemorrhage evacuation. We planned to conduct 
sensitivity analyses excluding patients who were severely 
injured at baseline. Dichotomous outcomes were 
analysed using relative risks (RR) or hazard ratios (HR), 
and continuous outcomes using a linear mixed model.
Results 1767 patients were included in this 
substudy. One- third of the patients had a baseline 
GCS (Glasgow Coma Score) of 3 (n=579) and 24% 
had unilateral or bilateral unreactive pupils. 46% of 
patients were scanned pre- randomisation and post- 
randomisation (n=812/1767), 19% were scanned 
only pre- randomisation (n=341/1767) and 35% were 
scanned only post- randomisation (n=614/1767). 
In all patients, there was no evidence that TXA 
prevents intraparenchymal haemorrhage expansion 
(estimate=1.09, 95% CI 0.81 to 1.45) or intracranial 
haemorrhage expansion in patients who underwent 
neurosurgical haemorrhage evacuation (n=363) 
(estimate=0.79, 95% CI 0.57 to 1.11). In patients 
scanned pre- randomisation and post- randomisation 
(n=812), there was no evidence that TXA reduces 
progressive haemorrhage (adjusted RR=0.91, 95% CI 
0.74 to 1.13) and new haemorrhage (adjusted 
RR=0.85, 95% CI 0.72 to 1.01). When patients with 
unreactive pupils at baseline were excluded, there was 
evidence that TXA prevents new haemorrhage (adjusted 
RR=0.80, 95% CI 0.66 to 0.98). In patients scanned 
post- randomisation (n=1431), there was no evidence 
Key messages
What is already known on this subject
 ► The CRASH-3 trial showed that tranexamic 
acid (TXA) administered within 3 hours of 
injury reduced early head injury deaths in 
patients not at or close to the point of death. 
TXA treatment may have prevented deaths 
from post- traumatic intracranial bleeding. 
However, there is little evidence on the effect 
of TXA on intracranial bleeding as measured 
on CT head scans of patients with traumatic 
brain injury (TBI). Prior to this study, a meta- 
analysis of two randomised trials of TXA in TBI 
showed a reduction in intracranial bleeding 
with TXA, on CT scans that were mandated 
after randomisation. But because the trials 
were small (n=249, n=229), the results were 
inconclusive.
What this study adds
 ► This substudy in 1767 CRASH-3 trial patients 
found that TXA may reduce intracranial 
bleeding, after patients with unreactive pupils 
at baseline were excluded. This study improves 
knowledge of the strengths and limitations of 
using routine scan data to examine the effects 
of a clinical trial intervention in TBI.
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of an increase in infarction with TXA (adjusted HR=1.28, 95% CI 0.93 
to 1.76). A larger proportion of patients without (vs with) a post- 
randomisation scan died from head injury (38% vs 19%: RR=1.97, 
95% CI 1.66 to 2.34, p<0.0001).
Conclusion TXA may prevent new haemorrhage in patients with 
reactive pupils at baseline. This is consistent with the results of the 
CRASH-3 trial which found that TXA reduced head injury death in 
patients with at least one reactive pupil at baseline. However, the 
large number of patients without post- randomisation scans and the 
possibility that the availability of scan data depends on whether a 
patient received TXA, challenges the validity of inferences made using 
routinely collected scan data. This study highlights the limitations 
of using routinely collected scan data to examine the effects of TBI 
treatments.
Trial registration number ISRCTN15088122.
INTRODUCTION
The CRASH-3 trial was a randomised placebo- controlled trial of 
the effects of tranexamic acid (TXA) on death and disability in 
patients with traumatic brain injury (TBI).1 The results showed 
that TXA (1 g over 10 min followed by 1 g over 8 hours) admin-
istered within 3 hours of injury reduces early head injury deaths 
in non- moribund patients (ie, not at or close to the point of 
death) (relative risk (RR) 0·74, 95% CI 0·58 to 0·94).2 3 While 
the trial was underway, the data monitoring committee asked 
for additional CT scan data to be collected ‘to explore if, why 
and how patients are affected by TXA’. Consequently, we devel-
oped a separate substudy protocol to explore this aim.4 While 
the CRASH-3 trial was ongoing and before the results were 
unblinded, we examined brain scans that were acquired as part 
of routine clinical practice from a proportion of CRASH-3 trial 
patients at selected trial sites. Most TBI patients presenting to 
hospital have CT head scans as part of their routine clinical care.5
In this substudy, we used routinely collected scans to examine 
the mechanism of action of TXA in TBI, particularly the effects 
of TXA on intracranial bleeding and infarction.4 6 If patients 
who receive TXA have less intracranial bleeding or more cere-
bral infarction on their scans compared with those who receive 
placebo, this information, along with the results of the main 
CRASH-3 trial, could improve understanding of the mechanism 
of action of TXA and help generalise the CRASH-3 trial results.7
METHODS
The background,8 protocol1 and results,2 3 of the CRASH-3 trial 
have been reported previously. Adults with head injury who were 
within 3 hours of injury, and had a baseline Glasgow Coma Score 
(GCS) of ≤12 or any intracranial bleeding on CT, and no signif-
icant extracranial bleeding were eligible for randomisation in 
hospital. The time window for eligibility was originally 8 hours, 
but in 2016 the protocol was changed to limit recruitment to 
within 3 hours of injury. Patients with TBI were randomly allo-
cated to receive TXA (loading dose 1 g over 10 min, then 1 g 
infusion over 8 hours) or placebo (0.9% sodium chloride), as an 
additional treatment to the standard management of TBI.
Patients, care givers and those assessing outcomes were 
masked to allocation.
Between July 2012 and January 2019, a total of 12 737 patients 
were randomised into the CRASH-3 trial in 175 hospitals across 
29 countries, of whom 9202 patients were randomised within 
3 hours of injury. This exploratory substudy (NCT01402882) 
was developed during the course of the CRASH-3 trial and the 
protocol and analysis plan were registered and published before 
the CRASH-3 trial was unblinded.4 6
Patients who fulfilled the eligibility criteria for the CRASH-3 
trial were eligible for this substudy (figure 1). While this 
substudy was underway, we restricted its eligibility to patients 
with GCS≤12 since many patients with mild TBI did not have 
a post- randomisation scan. In addition, patients needed to have 
had at least one CT scan within 28 days of randomisation, and 
be randomised before or during the time that the single assessor 
of the scans was on site.
Sample size
The CRASH-2 trial substudy in 249 patients with head injury and 
extracranial bleeding who had one CT head scan done before 
randomisation and another mandated after randomisation found 
a 15% reduction in the volume of intracranial bleeding with TXA 
(24 mL TXA and 28 mL placebo), a correlation of 0.6 between 
pre- randomisation and post- randomisation bleeding volumes 
and a SD of 28 mL.9 We used this data from the CRASH-2 
substudy to estimate an unadjusted sample size of 1542 patients 
to achieve 80% power to detect the expected treatment effect, 
which was then reduced to 987 patients with adjustment for pre- 
randomisation intracranial bleeding volume (1542×(1-(0.62)). 
We originally planned for this substudy to be conducted in 1000 
trial patients, but as data collection was underway, we increased 
the sample size because: (1) Many patients were recruited 
without a pre- randomisation CT scan, and so baseline adjust-
ment would not improve power to the extent that we expected. 
(2) Many patients had their post- randomisation scan done so 
soon after randomisation that any effect of TXA would not have 
sufficient opportunity to manifest on these scans, and their inclu-
sion might dilute the treatment effect. (3) Cerebral infarction 
occurred less frequently than intracranial bleeding so we would 
not be able to reliably examine the effects of TXA on infarction. 
The scan assessor had time to collect data from a maximum of 
2000 patients before the CRASH-3 trial completed recruitment 
and so this was the sample size we aimed for.
Participating hospitals
We invited CRASH-3 trial hospitals with high patient recruit-
ment to take part in this substudy. The UK and Malaysia were 
two of the highest recruiting countries in the CRASH-3 trial and 
stored the brain images that were collected as part of the routine 
clinical practice on electronic systems that could be accessed 
in- hospital by the substudy assessor. We invited the highest 
recruiting hospitals from these countries to have the routinely 
collected brain scans of CRASH-3 trial patients examined for 
the purpose of this substudy. If it was possible for the substudy 
assessor to perform an on- site examination of the electronic 
brain imaging done as part of routine care at that hospital site, 
and the trial principal investigator at the hospital site was willing 
to take part, the assessor visited the site and this substudy was 
conducted at that site. A list of participating hospitals is shown in 
online supplemental appendix 1. All regulatory, ethical and local 
approvals were in place before data collection began.
Outcome measurement
Non- contrast enhanced CT head scans that were done pre- 
randomisation and/or post- randomisation were examined. One 
outcome assessor (AM) who was blind to treatment allocation 
rated all scans in electronic (axial) format at each hospital using 
the local systems (ie, Picture Archiving and Communication 
System). The scans and neuroradiology reports were examined 
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and rated using a standardised data collection form (online 
supplemental appendix 2).
To assess intra- rater reliability, a sample of 90 patients’ scans 
were rated on two occasions by the same assessor, with the 
second reading done blind to the first. In this case, the assessor 
attended the same hospital site on two occasions to re- examine 
this sample of scans.
The CRASH-3 trial entry forms were completed by clinical 
research staff in participating hospitals and included a question 
on the type of haemorrhage seen on baseline CT.1 To examine 
inter- rater reliability, these CRASH-3 trial entry data that were 
completed by clinical research staff in participating hospitals were 
compared against the pre- randomisation scan readings done by 
the substudy outcome assessor. The second reading (substudy 
outcome assessor) was done blind to the first (CRASH-3 trial 
entry form assessors).
The ABC/2 method, a validated scale, was used to estimate 
the volume of epidural haemorrhage (EDH), intraparenchymal 
haemorrhage (IPH) (ie, contusion) and intraventricular haem-
orrhage (IVH). The assessor selected the slice on which each 
haemorrhage was most visible. A point in the centre of the 
haemorrhage was found and two measurements taken: (A) the 
maximal diameter; (B) the width perpendicular to A. For the 
measurement of depth, the maximum number of slices on which 
the haemorrhage is visible is multiplied by slice thickness (C). 
These three measurements (in cm) are multiplied together and 
then divided by 2 to estimate the volume in cubic centimetres (ie, 
ml). This method assumes haemorrhage has an almost spherical 
shape and shows good agreement with automated volumetric 
analyses in IPH and EDH.10 11
The maximum thickness of subdural haemorrhage (SDH) 
was measured and this value substituted into a novel formula 
to estimate volume (see online supplemental appendix 3). This 
formula was developed by substudy collaborators at University 
Hospitals Birmingham (UK).12 It takes the difference between 
two spheres to represent the subdural space and divides this by 
8 because the measurement is for unilateral SDH (divided by 2), 
which is typically thicker at the centre (divided by 2) and bound 
by superior- inferior and anterior- posterior cerebral axes (divided 
by 4).
The volume of subarachnoid haemorrhage (SAH) cannot be 
estimated, and so we recorded whether or not any SAH was 
visible (yes/no).
Primary outcome
The primary outcome was the volume of IPH (ie, contusions) 
seen on the post- randomisation scan, adjusted for baseline 
covariates: time from injury to pre- randomisation scan, GCS 
score, pupil reaction, systolic blood pressure, age and partici-
pating hospital.
In the protocol, we stated that the total volume of intracranial 
haemorrhage would be compared between treatment groups. 
After publishing the protocol but before unblinding the results,6 
Figure 1 Flowchart: inclusion criteria for the CRASH-3 trial (blue boxes show additional procedure for the substudy). GCS,Glasgow Coma Score.
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we proposed (in the Statistical Analysis Plan) that any effect of 
TXA on intracranial haemorrhage expansion may only be reli-
ably detected in IPH, which is less likely to require urgent neuro-
surgical evacuation than SDHs and EDHs. Large SDHs and 
EDHs may require urgent neurosurgical evacuation before we 
can examine any effect of TXA on the post- randomisation scans. 
Including these haemorrhages in the primary outcome may 
dilute any effect of TXA on intracranial haemorrhage expansion 
to the null.
Primary outcome analysis plan
A linear mixed model (LMM) was used to compare the mean 
change in IPH volume from pre- randomisation to post- 
randomisation between treatment groups.13 This model includes 
pre- randomisation and post- randomisation IPH volumes as 
correlated outcomes, with the mean post- randomisation IPH 
volume allowed to differ by treatment group and with the 
constraint of a common mean pre- randomisation IPH volume 
across treatment groups.13
The advantage of the LMM is that it allows all patients 
to be included in the analysis, even if they have missing pre- 
randomisation or missing post- randomisation scans. The IPH 
volume data from all patients with a pre- randomisation scan 
and all patients with a post- randomisation scan is included in 
the analysis. This approach is less biased and more efficient 
than a model that could only include patients with both pre- 
randomisation and post- randomisation scans (ie, analysis of 
covariance).13
Secondary outcomes and analysis plan
Progressive haemorrhage is defined as the proportion of patients 
with a post- randomisation scan with a total bleeding volume 
(IPH + IVH + EDH + SDH) that is more than 25% of the 
volume on the pre- randomisation scan. We will examine the 
effect of TXA on progressive haemorrhage (yes/no) using RRs 
and 95% CIs. Only patients scanned both pre- randomisation 
and post- randomisation can be included in this analysis.
New haemorrhage is defined as the proportion of patients with 
any type of bleeding (IPH/IVH/EDH/SDH/SAH) on the post- 
randomisation scan that was not seen on the pre- randomisation 
scan. We will examine the effect of TXA on new haemorrhage 
(yes/no) using RRs and 95% CIs. Only patients scanned both 
pre- randomisation and post- randomisation can be included in 
this analysis.
Cerebral infarction is defined as the proportion of patients 
with acute infarction seen on any post- randomisation brain 
scan done within 28 days of randomisation, excluding patients 
who had the same infarction on a pre- randomisation scan. All 
patients with a post- randomisation brain scan on which infarc-
tion could be assessed can be included in this analysis, irrespec-
tive of whether they were scanned pre- randomisation. We will 
examine the effect of TXA on cerebral infarction (yes/no) using 
HRs and 95% CIs. HRs were used (rather than RRs) because 
TXA may increase cerebral infarction after a more prolonged 
period after randomisation and the HR accounts for the time 
from randomisation to the time of the scan on which infarction 
was seen.
Composite poor outcome is defined as the proportion of 
patients with progressive haemorrhage, new haemorrhage, cere-
bral infarction or who had neurosurgery or died due to head 
injury. We will examine the effect of TXA on the composite poor 
outcome using RRs and 95% CIs. All substudy patients will be 
included in this analysis.
Volume of intracranial haemorrhage in patients who undergo 
surgical evacuation is defined as the total volume of intracra-
nial haemorrhage (IPH + IVH + EDH + SDH) seen on a scan 
done post- randomisation and post- neurosurgery in patients who 
undergo neurosurgical haemorrhage evacuation. A LMM was 
used to examine the effect of TXA on this outcome.
All secondary outcomes will be adjusted using time from 
injury to pre- randomisation scan (where appropriate), GCS 
score, pupil reaction, systolic blood pressure, age and partici-
pating hospital.
Statistical methods
We analysed the data as per the intention- to- treat principle and 
using the statistical software package Stata (V.15). The analyses 
involved no statistical imputation. We planned to conduct sensi-
tivity analyses excluding patients who were severely injured at 
baseline. We assessed the intra- rater and inter- rater reliability 
of dichotomous outcomes (ie, haemorrhage present/absent) and 
ordinal outcomes (ie, Marshall classification) using the Kappa 
(k) statistic, and continuous outcomes (ie, haemorrhage volume) 
using intraclass correlations (ICC).
RESULTS
Study population at baseline
One thousand seven hundred and sixty- seven participants 
recruited to the CRASH-3 trial between February 2013 and 
January 2019 were included in this substudy: 884 allocated to 
TXA group and 883 allocated to placebo group. The CONSORT 
(Consolidated Standards of Reporting Trials) diagram shows the 
disposition of patients by treatment group (figure 2) and table 1 
shows their pre- randomisation characteristics.
Sixty- five per cent of the patients (n=1147/1767) had a 
pre- randomisation CT scan (568 TXA group and 579 placebo 
group) and 71% of these patients (n=812/1147) also had a post- 
randomisation scan (399 TXA group and 413 placebo group). 
Thirty- five per cent were only scanned post- randomisation 
(n=614/1767) because they had a GCS of ≤12.
The median time to pre- randomisation scan was 2 hours after 
injury (IQR 1 hour to 2 hours). The median time to the post- 
randomisation scan was 23 hours after injury (IQR 8 hours to 
48 hours).
Of those with a pre- randomisation scan, 97% had intracranial 
pathology and 82% had intracranial haemorrhage (table 2). The 
median volume of SDH was 46 mL (IQR 27 to 71 mL), EDH was 
6 mL (IQR 2 to 21 mL), IPH was 1 mL (IQR 0.2 to 3.0 mL) and 
IVH was 0.5 mL (IQR 0.2 to 1.8 mL). The median volume of all 
haemorrhages combined was 37 mL (IQR 11 to 69 mL).
Primary outcome
IPH volumes were skewed and so medians are presented. The 
median IPH volume seen after randomisation was 0.5 mL (IQR 
0 to 4.6 mL) in the TXA group and 0.3 mL (IQR 0 to 3.1 mL) in 
the placebo group. Skewed data were transformed into a more 
normal distribution using log transformation. We used LMM to 
examine the effect of TXA on log- transformed IPH volumes. 
Covariates included age, time between injury and the pre- 
randomisation scan, baseline GCS score and systolic blood pres-
sure, and the participating hospital. Because IPH volumes were 
log- transformed, we present the anti- log of the effect estimates 
(and their 95% CIs) to indicate the relative reduction or increase 
in IPH volume with TXA. In all patients, there was no evidence 
that TXA prevents IPH expansion: estimate=1.06, 95% CI (0.84 
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to 1.35), p=0.62. This estimate cannot exclude a reduction or 
increase in IPH volume with TXA.
Secondary outcomes
Progressive haemorrhage. Among 812 patients scanned pre- 
randomisation and post- randomisation, 115 (29%) had progres-
sive haemorrhage in the TXA group and 130 (31%) in the 
placebo group (table 3), adjusted RR=0.91, 95% CI (0.74 to 
1.13), p=0.41.
New haemorrhage. Among 812 patients scanned pre- 
randomisation and post- randomisation, 318 (39%) had a newly 
detected haemorrhage on the post- randomisation scan: IPH was 
the most common (58%), followed by IVH (28%), SDH (17%), 
EDH (6%) and SAH (6%). Fifteen percent of patients with new 
haemorrhage had more than one type of new haemorrhage. TXA 
treated patients had fewer new haemorrhages (36% vs 42%: 
adjusted RR=0.85, 95% CI (0.72 to 1.01), p=0.069). When the 
134 patients with unilateral or bilateral unreactive pupils at base-
line were excluded, the adjusted RR for a new haemorrhage was 
0.80, 95% CI (0.66 to 0.98), p=0.030.
Cerebral infarction. Among all 1431 patients with a post- 
randomisation scan, 11% of patients (n=159/1431) had an 
acute cerebral infarction, adjusted HR=1.28, 95% (CI (0.93 to 
1.76), p=0.13.
Composite outcome. There is no evidence for a reduction 
in the composite with TXA (54% (n=480/884) versus 54% 
(n=478/883): adjusted RR=0.99, 95% CI (0.91 to 1.07), 
p=0.83.
Intracranial haemorrhage in patients who underwent surgical 
haemorrhage evacuation. Three hundred and sixty- three patients 
(21%) underwent neurosurgical haemorrhage evacuation. The 
median volume of haemorrhage seen after randomisation and 
neurosurgery was 36 mL (IQR 16 to 61 mL) in the TXA group 
and 38 mL (IQR 18 to 70 mL) in the placebo group. Haemor-
rhage volume data were skewed and so log- transformed. We 
used LMM to examine the effect of TXA on log- transformed 
haemorrhage volumes. Covariates included age, time between 
injury and the pre- randomisation scan, baseline GCS score 
and systolic blood pressure, and the participating hospital. We 
present the anti- log of the effect estimates and their 95% CIs. 
There is no evidence that TXA prevents haemorrhage expansion 
in patients who had neurosurgical haemorrhage evacuation: esti-
mate=0.79, 95% CI (0.57 to 1.11), p=0.63.
Inter-rater and intra-rater reliability
Inter- rater reliability for pre- randomisation haemorrhage was 
moderate for most haemorrhage types. EDH ratings agreed 
between raters in 88% of patients (k=0.57, p<0.0001), IVH in 
Figure 2 CONSORT (Consolidated Standards of Reporting Trials) diagram on flow of patients in the CRASH-3 trial substudy.
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88% (k=0.50, p<0.0001), SAH in 77% (k=0.50, p<0.0001), 
SDH in 74% (k=0.43, p<0.0001) and IPH in 65% (k=0.33, 
p<0.0001). Intra- rater reliability for haemorrhage seen pre- 
randomisation was fair- to- moderate for most haemorrhage types. 
IPH ratings agreed in 65% of patients (k=0.32, p=0.0006), 
SDH in 61% (k=0.33, p<0.0001) and IVH in 94% (k=0.42, 
p<0.0001). ICCs between individual readings for each patient 
(ICC=0.70, 95% CI 0.58 to 0.80) and mean readings for each 
patient (ICC=0.83, 95% CI 0.73 to 0.89) indicate moderate- to- 
good reliability.
Missing post-randomisation scans
Three hundred and thirty- five patients did not have post- 
randomisation scans performed. A larger proportion of patients 
without (vs with) a post- randomisation scan had a mild GCS 
score (8% vs 4%: RR=1.87, 95% CI (1.22 to 2.87), p=0.004) 
or had bilateral unreactive pupils at baseline (22% vs 11%: 
RR=2.04, 95% CI 1.59 to 2.62, p<0.0001). A larger propor-
tion of patients without (vs with) a post- randomisation scan 
died from head injury (38% vs 19%: RR=1.97, 95% CI 1.66 to 
2.34, p<0.0001) (tables 4 and 5). There was no evidence that 
TXA increases the risk of not having a post- randomisation scan: 
19% (n=169/884) versus 19% (n=166/882), RR=1.02, 95% CI 
(0.84 to 1.23), p=0.87.
Outcomes are presented separately for patients randomised 
within 3 hours of injury and patients randomised after 3 hours of 
injury (table 3 and online supplemental appendix 4).
DISCUSSION
Substudy findings in context of CRASH-3 trial results
The CRASH-3 trial showed that TXA reduces early head 
injury deaths in non- moribund patients.2 3 In this substudy, we 
attempted to obtain more information about the mechanism of 
TXA by looking at the brain scans of patients in each trial arm. 
Performing brain scans was not a requirement of the CRASH-3 
trial protocol and so we reviewed clinically indicated scans from 
a subset of trial patients. Using the date and time of the scans, 
and the date and time of randomisation into the trial, we were 
able to confirm whether clinically indicated scans were done 
before, after, or both before and after randomisation. We did 
not find evidence for a difference in the volume of intracranial 
bleeding between TXA and control patients on scans done post- 
randomisation. Comparing the scans of patients who had both 
pre- randomisation and post- randomisation scans, we did not 
find evidence for a reduction in intracranial bleeding with TXA. 
We did find that the TXA group had fewer new haemorrhages, if 
we excluded patients whose baseline clinical exam indicated one 
or both non- reactive pupils.
However, because a large proportion of patients with milder 
injuries were not scanned after randomisation, we were unable 
to examine the effect of TXA in the population most likely to 
benefit. The majority of patients in this substudy had severe 
head injury and one- third had a GCS score of 3. This was partly 
because we chose high recruiting hospitals to participate in this 
substudy, many of which were also major trauma centres, which 









  Male 1413 (80%) 701 (79%) 712 (81%)
  Female 354 (20%) 183 (21%) 171 (19%)
Age
  Median (IQR) age in years 45 (29 to 63) 45 (29 to 64) 45 (29 to 63)
Glasgow Coma Score (GCS)
  Mild (13 to 15) 92 (5%) 47 (5%) 45 (5%)
  Moderate (9 to 12) 532 (30%) 264 (30%) 268 (30%)
  Severe (3 to 8) 1143 (65%) 573 (65%) 570 (65%)
  Median (IQR) GCS 7 (3 to 10) 7 (3 to 10) 7 (3 to 10)
Pupil reaction
  Both react 1289 (73%) 637 (72%) 652 (74%)
  One reacts 202 (11%) 97 (11%) 105 (12%)
  None react 232 (13%) 124 (14%) 108 (12%)
  Unable to assess 43 (2%) 25 (3%) 18 (2%)
  Unknown 1 (<1%) 1 (<1%) 0 (0%)
Systolic blood pressure
  <90 27 (2%) 14 (2%) 13 (1%)
  90 to 119 370 (21%) 194 (22%) 176 (20%)
  ≥120 1362 (77%) 672 (76%) 690 (78%)
  Unknown 8 (<1%) 4 (<1%) 4 (<1%)
Median (IQR) systolic blood 
pressure
136 (120 to 155) 136 (120 to 156) 136 (121 to 
154)
Hours since injury
  ≤1 166 (9%) 77 (9%) 89 (10%)
  >1 to ≤3 1184 (67%) 596 (67%) 588 (67%)
  >3 417 (24%) 211 (24%) 206 (23%)
Pre- randomisation CT scan
  Yes 1147 (65%)* 568 (64%) 579 (66%)
  No 615 (35%) 313 (35%) 302 (34%)
  Unknown 5 (<1%) 3 (<1%) 2 (<1%)
Median (IQR) hours from 
injury to scan
1.8 (1.4 to 2.4) 1.8 (1.5 to 2.4) 1.8 (1.4 to 
2.3)
Data are n (%) of patients, unless otherwise indicated.
*12 unavailable due to technical problems (4 TXA and 8 placebo).
TXA, tranexamic acid.
Table 2 Baseline CT scan characteristics
Patients with baseline CT scan
(n=1147)
Intracranial bleeding
  Intraparenchymal 709 (62%)
  Intraventricular 184 (16%)
  Subdural 732 (64%)
  Epidural 215 (19%)
  Subarachnoid 829 (72%)
Oedema and infarction
  Oedematous lesions 177 (15%)
  Acute cerebral infarction 13 (1%)
Mass effect
  Midline shift 503 (44%)
   Median (IQR) degree of shift in mm 6 (4 to 12)
  Sulcal effacement 609 (53%)
  Ventricular effacement 456 (40%)
Marshall classification
  Diffuse injury I 25 (2%)
  Diffuse injury II 533 (46%)
  Diffuse injury III 60 (5%)
  Diffuse injury IV 30 (3%)
  Non- evacuated mass lesion 487 (43%)
  Unknown 12 (1%)
Data are n (%) of patients, unless otherwise indicated.
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receive a large proportion of severely injured patients. The 
CRASH-3 trial found a reduction in head injury death within 
24 hours of injury in non- moribund patients.2 3 Given the base-
line status of the included patients, it would be difficult to see 
a treatment effect on CT scans in this substudy, which included 
a large proportion of moribund patients. The baseline data 
show that patients with severe TBI and unreactive pupils have 
the largest volumes of intracranial bleeding.14 TXA may have 
little potential to prevent intracranial haemorrhage progression 
in these patients, and their inclusion may dilute any treatment 
effect. In fact, much like the CRASH-3 trial which found a 
reduction in head injury death when patients with unreactive 
pupils were excluded,2 3 when those with unreactive pupils 
are excluded in this substudy, there is some evidence that TXA 
prevents new haemorrhage.
Strengths and weaknesses in relation to other studies
With a limited clinical trial budget, we had to rely on scans that 
were ordered by treating physicians as part of trial patients’ 
clinical management. This allowed us to conduct the largest 
mechanistic study of TXA in TBI to date. However, there 
are methodological flaws associated with the use of routine 
imaging. Previous trials in this area were smaller and mandated 
Table 3 Effect of TXA on new and progressive haemorrhage
TXA group Placebo group RR (95% CI) unadjusted
P value




  ≤3 hours since injury 108/261 (41%) 129/284 (45%) 0.91 (0.75 to 1.10) 0.34 0.89 (0.73 to 1.08) 0.22
  >3 hours since injury 36/138 (26%) 45/129 (35%) 0.75 (0.52 to 1.08) 0.12 0.69 (0.48 to 0.99) 0.044
  All patients 144/399 (36%) 174/413 (42%) 0.86 (0.72 to 1.02) 0.079 0.85 (0.72 to 1.01) 0.069
Exclude unreactive pupils (one/both) 108/332 (33%) 140/346 (40%) 0.80 (0.66 to 0.98) 0.033 0.80 (0.66 to 0.98) 0.030
Progressive haemorrhage
  ≤3 hours since injury 76/261 (29%) 88/284 (31%) 0.94 (0.73 to 1.22) 0.64 0.92 (0.72 to 1.19) 0.53
  >3 hours since injury 39/138 (28%) 42/129 (33%) 0.87 (0.60 to 1.25) 0.45 0.86 (0.58 to 1.28) 0.46
  All patients 115/399 (29%) 130/413 (31%) 0.92 (0.74 to 1.13) 0.41 0.91 (0.74 to 1.13) 0.41
Exclude unreactive pupils (one/both) 92/332 (28%) 111/346 (32%) 0.86 (0.69 to 1.09) 0.22 0.87 (0.69 to 1.10) 0.24
*Adjusted for time from injury to pre- randomisation scan, age, GlasgowComa Score, pupil reaction, systolic blood pressure and participating hospital.
RR, relative risk; TXA, tranexamic acid.
Table 4 Patients with post- randomisation scans by baseline injury severity and treatment group
Patients with post- 
randomisation scan
(n=1431/1767) TXA group Placebo group RR (95% CI)
P value
(two- tailed)
Glasgow Coma Score (GCS)   
  Mild (GCS 13 to 15) 64 (4%) 32/47 (68%) 32/45 (71%) 0.96 (0.73 to 1.26) 0.75
  Moderate (GCS 9 to 12) 425 (30%) 211/264 (80%) 214/267 (80%) 1.00 (0.92 to 1.09) 0.95
  Severe (GCS 3 to 8) 942 (66%) 472/573 (82%) 470/570 (82%) 1.00 (0.95 to 1.05) 0.97
Pupil reaction   
  Both react 1064 (74%) 529/637 (83%) 535/651 (82%) 1.01 (0.96 to 1.06) 0.68
  One reacts 174 (12%) 83/97 (86%) 91/105 (87%) 0.99 (0.88 to 1.10) 0.82
  None react 157 (11%) 82/124 (66%) 75/108 (69%) 0.95 (0.80 to 1.14) 0.59
  Unable to assess 35 (2%) 20/25 (80%) 15/18 (83%) 0.96 (0.72 to 1.28) 0.78
RR, relative risk; TXA, tranexamic acid.
Table 5 Patients without post- randomisation scans by baseline injury severity and treatment group
Patients without post- randomisation scan
(n=335/1767) TXA group Placebo group RR (95% CI)
P value
(two- tailed)
Glasgow Coma Score (GCS)   
  Mild (GCS 13 to 15) 28 (8%) 15/47 (32%) 13/45 (29%) 1.10 (0.59 to 2.06) 0.75
  Moderate (GCS 9 to 12) 106 (32%) 53/264 (20%) 53/267 (20%) 1.01 (0.72 to 1.42) 0.95
  Severe (GCS 3 to 8) 201 (60%) 101/573 (18%) 100/570 (18%) 1.00 (0.78 to 1.29) 0.97
Pupil reaction
  Both react 224 (67%) 108/637 (17%) 116/651 (18%) 0.95 (0.75 to 1.21) 0.68
  One reacts 28 (8%) 14/97 (14%) 14/105 (13%) 1.08 (0.54 to 2.16) 0.82
  None react 75 (22%) 42/124 (34%) 33/108 (31%) 1.11 (0.76 to 1.62) 0.59
  Unable to assess 8 (2%) 5/25 (20%) 3/18 (17%) 1.20 (0.32 to 4.46) 0.79
RR, relative risk; TXA, tranexamic acid.
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scans post- randomisation.9 15 16 They had fewer missing post- 
randomisation scans and in this respect are less vulnerable to 
bias.
Substudy weaknesses
Although using data collected as part of standard practice in clin-
ical trials can reduce costs, there are threats to validity.17 18 In 
the context of TBI, an initial or repeat CT brain scan may not 
be performed in patients with mild or unsurvivable injury, and 
if a second scan is clinically indicated, patients may die before it 
can be conducted. These missing scans threaten the validity of 
any inferences. A recent systematic review revealed that there 
is substantial variability in how missing data are handled in 
TBI research.19 If there is minimal missing data, the impact on 
effect estimates can be negligible.20 In this substudy, one- fifth 
of the patients did not receive a post- randomisation CT brain 
scan, which may be related to their prognosis and/or response 
to TXA.21 Because TXA reduces the risk of head injury death,2 
TXA- treated patients may not have had a clinical indication for a 
post- randomisation scan and placebo- treated patients may have 
died before the opportunity for scanning. Therefore, a similar 
proportion of patients with missing post- randomisation scans in 
TXA and placebo groups does not exclude the possibility of bias.
One- fifth of the patients had neurosurgical haemorrhage 
evacuation before the post- randomisation scan. Haemorrhage 
seen post- randomisation and post- neurosurgery may reflect the 
combined effects of TXA and neurosurgical haemorrhage evac-
uation. If TXA reduces intracranial haemorrhage, it may reduce 
the need for neurosurgical haemorrhage evacuation. Patients 
who receive placebo and go on to have their intracranial bleed 
evacuated may have less blood on their post- randomisation scan 
than those who receive TXA and do not undergo evacuation.
The clinical value of an arbitrarily defined progressive haem-
orrhage outcome is limited. An apparent increase in haemor-
rhage between scans may not be generalisable because this may 
have different clinical implications depending on the type of 
haemorrhage that expands. Even though SDH/EDH are typi-
cally larger than IPH/IVH, a 25% increase in SDH/EDH could 
be managed surgically in the first few hours of injury with good 
prognostic outcome,22 but a 25% increase in IPH/IVH may have 
worse prognostic outcome.23
Outcomes may not have been accurately measured. The ABC/2 
method has not been validated in all types of haemorrhage (ie, 
IVH) and its accuracy is reduced if bleeds are irregularly shaped. 
SDH volume estimation was based on a novel approach whose 
reliability is to be confirmed. Unclotted bleeding, micro- bleeding 
and infarction are not clearly visible on CT, especially soon 
after injury.24–26 Furthermore, reliability ratings indicate that 
there were discrepancies in ratings between and within asses-
sors. Discrepancies between raters should be expected because 
the substudy assessor examined scans and radiology reports 
that are usually written post- randomisation, while randomisa-
tion into the CRASH-3 trial was based on information known 
pre- randomisation (eg, verbal report from clinician). Discrepan-
cies in the substudy assessor’s measurements of the same scans 
should be expected because Reading 1 was done as part of an 
audit which primarily involved estimating the volume of the 
largest bleeds, while Reading 2 was done as part of the substudy 
procedure and examined all bleeds.
There were two sources of null bias. First, many post- 
randomisation scans were done very soon after randomisation, 
when there would have been little opportunity for any effect 
of TXA to become apparent. This is particularly relevant for 
types of haemorrhage that usually have smaller volumes, such 
as IPH, which the baseline data suggest expand at 0.4 mL/hour 
(IQR 0.1 to 2 mL/hour).14 Second, a large proportion of patients 
had severe (and possibly unsurvivable) head injuries at baseline. 
Because the CRASH-3 trial did not find evidence for a reduction 
in head injury death in severely injured patients, their inclusion 
in this substudy may have also diluted any treatment effect.
Implications for future research
The US National Institutes of Health propose that ‘the link 
between prevention of haemorrhage growth (with haemostatic 
therapy) and clinical outcome’ can be studied using radiological 
outcomes.27 From our experience of conducting this substudy, 
we believe that this should be done in a large high- quality 
randomised trial where all randomised patients are scanned 
post- randomisation. Inclusion should not be based on post- 
randomisation events or restricted in terms of injury severity. 
MRI is more sensitive than CT in detecting micro- bleeding25 and 
infarction.26
CONCLUSION
This substudy was nested within the CRASH-3 trial and its results 
are consistent with the trial results. Here we found that TXA 
may prevent new haemorrhage in patients with reactive pupils 
at baseline, and the CRASH-3 trial found that TXA reduced 
head injury death in patients with at least one reactive pupil at 
baseline. While the use of routinely collected scans allowed this 
substudy to achieve a sample size that is considerably larger than 
previous studies in this area, this also resulted in many method-
ological flaws. Most importantly, the large number of patients 
without post- randomisation scans and the possibility that the 
availability of scan data depends on whether a patient received 
TXA, challenges the validity of treatment effect estimates. This 
study highlights the strengths and limitations of using routinely 
collected scan data to examine the effects of TBI treatments.
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